To include your compound in the COVID-19 Resource Center, submit it here.

Iclaprim: Phase III started

Motif began the identical, double-blind, international Phase III REVIVE-1 and REVIVE-2 trials to evaluate IV

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE